Division of Pfizer Inc.
Latest From Monsanto Co.
Executive All-Change: Bayer's Weinand To Join Sanofi, While Sanofi's Oelrich To Take His Place At Bayer
A head-spinning change of executives in Europe's leading pharmaceutical companies will see a new head of pharmaceuticals at Bayer and the former incumbent fetching up at Sanofi in the US.
Start-Up Spotlight: Two Pore Guys, Gearing Up To Market Unique Handheld Nanopore Sensor After Inking Agreement With Monsanto
Two Pore Guys has developed a digital, hand-held single-molecule biosensor capable of detecting a wide array of molecules including viruses, bacteria, antibodies and pathogens. The company plans to send the first-generation of the developer kits to strategic partners in mid-2018 and already has inked agreements with human diagnostics, animal health companies and agribusiness giant Monsanto Co.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.
The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Terry Crews, CFO
Robb Fraley, CTO
Hugh Grant, COO
William Ide, SVP
- Contact Info
Phone: (314) 694-1000
800 North Lindbergh Boulevard
St. Louis, MO 63167
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.